Thryvtrx
5 known investors
Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). It is running a clinical study (Wave II) for people with Long QT Syndrome Type 2.
Founders & leadership
PF
Paul F. TruexChairman of the Board & Chief Executive Officer
DO
Debra OdinkPresident & Chief Development Officer
AS
Amy SehnertChief Medical Officer
MK
Matt KilleenChief Business Officer
Board
SD
Saumya DasChief Scientific Advisor
Investors · 5
Competitors · 2
by search overlap
Medscape68 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
UPMC46 shared keywordsUPMC operates a network of hospitals and health care facilities, offering medical services and specialties such as cancer care, cardiology, neurosciences, orthopaedics, and behavioral health. It provides patient tools for finding doctors, locating facilities by region, and accessing patient portals.
Companies competing with Thryvtrx for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Thryvtrx do?
- Thryv Therapeutics is a clinical-stage biotech developing precision-medicine treatments for genetic arrhythmia syndromes and acquired cardiometabolic diseases using selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1). It is running a clinical study (Wave II) for people with Long QT Syndrome Type 2.
- Who are Thryvtrx's investors?
- Thryvtrx's investors include Lumira Ventures, adMare BioInnovations, Amzak Health, CTI Life Sciences Fund L.P., Fonds de solidarité FTQ.